McKesson Corporation (MCK)
NYSEHealth CareMedical DistributionSnapshot 2026-07-07
$807.33+2.95%
Close 2026-07-07 · 1-day change
Reading MCK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MCK free→NYSEHealth CareMedical DistributionSnapshot 2026-07-07
Reading MCK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MCK free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is stable, supported by strong recent financial performance and management's commitment to growth targets.
The market currently prices MCK as cheap compared to its peers, with a slight expectations gap. The valuation reflects a justified position, indicating that the market does not fully account for its recent strong performance.
Fundamentals are likely to remain stable, as management has reaffirmed long-term earnings growth targets and is expanding its Oncology & Multispecialty segment. However, there is a moderate risk due to recent management changes and historical performance volatility.
The thesis hinges on the performance of sector bellwethers like CAH, COR, and HSIC, which could influence MCK's trajectory. Additionally, any potential guidance cuts from management could negatively impact sentiment.
Overall, MCK appears to be in a solid position for the next 1 to 3 years, but it is essential to monitor sector trends and management execution closely. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat and the reaffirmation of long-term earnings per share (EPS) growth targets, which signal strong financial performance. There are no significant threats noted that could weaken this positive outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Confirming the adjusted EPS guidance of $43.80 to $44.60 shows strong growth momentum. This helps validate management's long-term growth targets.
Confirms:Fiscal 2027 adjusted EPS guidance confirmed within the range of $43.80 to $44.60.
Disproves:Guidance is lowered below $43.80. This shows weaker growth expectations.
Why it matters: More share repurchases can show trust in the company's finances.
Confirms:There is an announcement for more share repurchases beyond $7.7 billion.
Disproves:No new share repurchase announcements or a reduction in the current program.
Why it matters: If the outlook is confirmed, it shows trust in the company's growth.
Confirms:Management will confirm the fiscal 2026 outlook in the next earnings call.
Disproves:Management cuts the outlook for fiscal 2026.
Why it matters: The new CFO's methods may change financial choices and company plans.
Confirms one read:The new CFO outlines a clear financial strategy that aligns with company goals.
Confirms the other:The transition may cause uncertainty or changes in financial plans.
Why it matters: Finalizing the credit deal would give more financial options and help growth.
Confirms:Management says the new credit agreement is done.
Disproves:There are delays or problems in finalizing the new credit agreement.
Why it matters: An increase in EPS guidance would show stronger growth expectations for the company.
Confirms:Management raises EPS guidance for fiscal 2026 during the next earnings call.
Disproves:Management maintains or lowers EPS guidance for fiscal 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.